Business Segments · Development expenses
Business Segments — Development expenses
Vertex Pharmaceuticals Business Segments — Development expenses decreased by 1.9% to $756.6M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 2.2%, from $773.6M to $756.6M. Over 3 years (FY 2022 to FY 2025), Business Segments — Development expenses shows an upward trend with a 17.2% CAGR.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2022
Last reportedQ1 2026May 5, 2026
How to read this metric
Higher spending indicates active progression of the pipeline, while lower spending may suggest a pause in clinical activity.
Detailed definition
Costs associated with clinical trials, regulatory filings, and the advancement of drug candidates through the developmen...
Peer comparison
Often grouped with research as R&D; peers vary in how they split these specific phases.
Metric ID:
vrtx_segment_pharmaceuticals_development_expensesHistorical Data
17 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $478.4M | $478.4M | $478.4M | $478.4M | $614.33M | $614.33M | $614.33M | $614.33M | $593M | $759.3M | $682.1M | $791.4M | $773.6M | $769.1M | $767.7M | $771.2M | $756.6M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +28.4% | +0.0% | +0.0% | +0.0% | -3.5% | +28.0% | -10.2% | +16.0% | -2.2% | -0.6% | -0.2% | +0.5% | -1.9% |
| YoY Change | — | — | — | — | +28.4% | +28.4% | +28.4% | +28.4% | -3.5% | +23.6% | +11.0% | +28.8% | +30.5% | +1.3% | +12.5% | -2.6% | -2.2% |
Range$478.4M – $791.4M
CAGR+12.1%
Avg YoY Growth+16.4%
Median YoY Growth+23.6%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's business segments — development expenses?
- Vertex Pharmaceuticals (VRTX) reported business segments — development expenses of $756.6M in Q1 2026.
- How has Vertex Pharmaceuticals's business segments — development expenses changed year-over-year?
- Vertex Pharmaceuticals's business segments — development expenses decreased by 2.2% year-over-year, from $773.6M to $756.6M.
- What is the long-term trend for Vertex Pharmaceuticals's business segments — development expenses?
- Over 3 years (2022 to 2025), Vertex Pharmaceuticals's business segments — development expenses has grown at a 17.2% compound annual growth rate (CAGR), from $1.91B to $3.08B.
- What does business segments — development expenses mean?
- Spending on clinical trials and the process of getting drugs approved for market.